<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To clarify the role of ADAMTS-13 in the pathogenesis of <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> in <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) we evaluated ADAMTS-13 profile (metalloprotease antigen levels, anti-ADAMTS-13 autoantibody levels, activity) in distinct patient groups according to disease activity, extent of cumulative tissue damage and history of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> or end-organ damage </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-one <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> patients were analysed </plain></SENT>
<SENT sid="2" pm="."><plain>ADAMTS-13 metalloprotease antigen levels and anti-ADAMTS-13 autoantibodies were evaluated by ELISA </plain></SENT>
<SENT sid="3" pm="."><plain>ADAMTS-13 activity was measured by Fluorescence resonance energy transfer (FRET) technique </plain></SENT>
<SENT sid="4" pm="."><plain>ADAMTS-13 metalloprotease antigen levels were significantly decreased in patients with Systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) &gt;1 (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>ADAMTS-13 metalloprotease antigen levels also exhibited a significant inverse correlation with anti-dsDNA levels (r = -0.60, p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Anti-ADAMTS-13 autoantibodies were marginally higher in patients with positive anti-dsDNA (p = 0.08) </plain></SENT>
<SENT sid="7" pm="."><plain>Additionally, patients with positive anti-ADAMTS-13 autoantibodies exhibited the lowest activity levels (p��&lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>To our knowledge ADAMTS-13 profile in SLE has not been studied in regard to composite structured indices </plain></SENT>
<SENT sid="9" pm="."><plain>The results of this study suggest that in patients with active SLE or considerable cumulative tissue damage, ADAMTS-13 levels may be decreased and anti-ADAMTS-13 autoantibodies may partially mediate this reduction </plain></SENT>
<SENT sid="10" pm="."><plain>Further evaluation of ADAMTS-13 profile may explain its role in the pathogenesis of <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> in <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> patients and reveal a potential prognostic marker of microthrombotic manifestations in SLE </plain></SENT>
</text></document>